Appendix 4C - quarterly
January 29, 2021
BNC105 / Nivolumab Treatment Completed in Phase 2 Trial
January 20, 2021
Publication of Positive BNC210 Phase 2a Data in GAD Patients
January 18, 2021
BNO Initiates 7-Day Dosing Pharmacokinetic Study of BNC210
January 4, 2021
Lapse of Employee Share Options & Warrants
December 18, 2020
Appendix 3Y
November 24, 2020
Results of Meeting
November 20, 2020
Executive Chairmans 2020 AGM Presentation
November 20, 2020
Bionomics Licenses Drug Candidate BNC101 to Carina Biotech
November 19, 2020
Historical ASX announcements can be found here.